US approves AZ’ hairy cell leukaemia drug

14th September 2018 Uncategorised 0

AstraZeneca and its biologics R&D arm MedImmune have bagged US approval of Lumoxiti for the treatment of hairy cell leukaemia (HCL), marking the first new treatment option in 20 years.

More: US approves AZ’ hairy cell leukaemia drug
Source: News